These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10220597)

  • 41. The preventive polypill--much promise, insufficient evidence.
    Reddy KS
    N Engl J Med; 2007 Jan; 356(3):212. PubMed ID: 17229947
    [No Abstract]   [Full Text] [Related]  

  • 42. Medication adherence: a call for action.
    Bosworth HB; Granger BB; Mendys P; Brindis R; Burkholder R; Czajkowski SM; Daniel JG; Ekman I; Ho M; Johnson M; Kimmel SE; Liu LZ; Musaus J; Shrank WH; Whalley Buono E; Weiss K; Granger CB
    Am Heart J; 2011 Sep; 162(3):412-24. PubMed ID: 21884856
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.
    Briggs A; Mihaylova B; Sculpher M; Hall A; Wolstenholme J; Simoons M; Deckers J; Ferrari R; Remme WJ; Bertrand M; Fox K;
    Heart; 2007 Sep; 93(9):1081-6. PubMed ID: 17135223
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Fundamentals of economic analysis.
    Mark DB; Simons TA
    Am Heart J; 1999 May; 137(5):S38-40. PubMed ID: 10220594
    [No Abstract]   [Full Text] [Related]  

  • 45. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Consortium perspective: what constitutes a useful economic study?
    Chen C; Vlasses PH
    Am Heart J; 1999 May; 137(5):S71-4. PubMed ID: 10220601
    [No Abstract]   [Full Text] [Related]  

  • 46. Past the wall in cardiovascular R&D.
    Topol EJ
    Nat Rev Drug Discov; 2009 Apr; 8(4):259. PubMed ID: 19348004
    [No Abstract]   [Full Text] [Related]  

  • 47. Rational use of medications: if Canada can't do it ..
    Califf RM
    CMAJ; 2009 Jul; 181(1-2):15-6. PubMed ID: 19581612
    [No Abstract]   [Full Text] [Related]  

  • 48. Prices For Common Cardiovascular Drugs In The US Are Not Consistently Aligned With Value.
    Campbell JD; Belozeroff V; Whittington MD; Rubin RJ; Raggi P; Briggs AH
    Health Aff (Millwood); 2018 Aug; 37(8):1298-1305. PubMed ID: 30080450
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel cardiovascular therapeutics and the risk of financial toxicity.
    Gunn AH; Pendyal A
    Nat Rev Cardiol; 2024 Jun; 21(6):349-350. PubMed ID: 38485769
    [No Abstract]   [Full Text] [Related]  

  • 50. Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study.
    Czernichow S; Knol MJ; Fezeu L; Grobbee DE
    Eur J Prev Cardiol; 2012 Jun; 19(3):484-9. PubMed ID: 21464100
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. ACE inhibitors in the management of congestive heart failure: comparative economic data.
    Boyko WL; Glick HA; Schulman KA
    Am Heart J; 1999 May; 137(5):S115-9. PubMed ID: 10220611
    [No Abstract]   [Full Text] [Related]  

  • 52. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK.
    Becerra V; Gracia A; Desai K; Abogunrin S; Brand S; Chapman R; García Alonso F; Fuster V; Sanz G
    BMJ Open; 2015 May; 5(5):e007111. PubMed ID: 25991449
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Coverage of drug costs: reference-based pricing.
    McGregor M
    Can J Cardiol; 1998 May; 14(5):666-8. PubMed ID: 9627520
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?
    Sigvant B; Henriksson M; Lundin F; Wahlberg E
    Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):254-61. PubMed ID: 21450673
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Occlusion in the Flow of New Drugs for Cardiovascular Disease.
    Ringel MS; Shah NA; Baedeker M; Lim CT; Lamichhane A; Schulze U
    Clin Pharmacol Ther; 2017 Aug; 102(2):246-253. PubMed ID: 28378877
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. The value of cost-effectiveness analyses for reimbursement decisions: perspectives from Medicare.
    Sheingold SH
    Am Heart J; 1999 May; 137(5):S81-6. PubMed ID: 10220604
    [No Abstract]   [Full Text] [Related]  

  • 57. Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?
    Noubiap JJ; Nansseu JR
    Vasc Health Risk Manag; 2015; 11():503-6. PubMed ID: 26345154
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reference-based pricing of prescription drugs.
    McLaughlin PR
    Can J Cardiol; 1997 Jan; 13(1):31-2. PubMed ID: 9039062
    [No Abstract]   [Full Text] [Related]  

  • 59. Costly Medications Add Urgency to Physician-Patient Affordability Discussions.
    Kuehn BM
    Circulation; 2018 Jan; 137(3):298-299. PubMed ID: 29335289
    [No Abstract]   [Full Text] [Related]  

  • 60. Cardiovascular disease in primary care: concordance and risk reduction.
    Knapton M
    Br J Gen Pract; 2012 Jun; 62(599):284-5. PubMed ID: 22687202
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.